Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-crystallin B chain is a small heat shock protein encoded by the CRYAB gene in humans. It serves as a molecular chaperone that binds misfolded proteins to prevent their aggregation, protects cells from stress-induced apoptosis, and maintains the architecture of muscle and lens cells. This protein is abundant in the eye lens, where its stability is crucial for lens transparency, but it also exists in many tissues including muscle, heart, and brain. Mutations in CRYAB are associated with inherited cardiac and skeletal muscle myopathies, cataract, cancers, and neurodegenerative diseases. Alpha-crystallin B chain operates as part of large, heterogeneous complexes, and its activity can be modulated by post-translational modifications[1][3][5][8].
Not a direct drug target; however, in preclinical models, modulation of chaperone function or expression can alter protein aggregation in disease contexts
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-crystallin B chain (CRYAB).